Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2022

08-10-2022 | Hypersensitivity Pneumonitis | Interstitial Lung Disease (S Dhooria, Section Editor)

New Paradigms in Hypersensitivity Pneumonitis

Authors: Bineet Ahluwalia, Sheetu Singh

Published in: Current Pulmonology Reports | Issue 4/2022

Login to get access

Abstract

Purpose of Review

This review aims to briefly discuss the new paradigms explored in the recent past especially for the diagnosis and treatment of hypersensitivity pneumonitis (HP).

Recent Findings

HP has now been classified into non-fibrotic and fibrotic phenotypes. The diagnosis of non-fibrotic and fibrotic HP has been categorized into “typical,” “compatible,” and “indeterminate” in terms of radiology and histopathology, grading the degree of diagnostic confidence. The newly explored role of antifibrotic drugs provides a treatment prospect for patients with fibrotic HP whose options were largely limited to corticosteroids and immunosuppressants.

Summary

The official guidelines provide us with a systematic approach towards making a confident diagnosis of HP and its subtypes. Recent pharmacological studies have enlightened our knowledge with a variety of treatment options, especially for fibrotic HP. However, a multitude of questions still remain unanswered.
Literature
1.
Campbell JM. Acute symptoms following work with hay. Br Med J. 1932;11:1143.
2.
Pepys JP, Jenkins PA, Festenstein GN, Lacey M, Gregory PH, Skinner FA. Farmer’s lung thermophilic actinomycetes as a source of “farmer’s lung hay” antigen. The Lancet. 1963;282(7308):607–11.CrossRef
3.
Richerson HB, Bernstein IL, Fink JN, Hunninghake GW, Novey HS, Reed CE, Salvaggio JE, Schuyler MR, Schwartz HJ, Stechschulte DJ. Guidelines for the clinical evaluation of hypersensitivity pneumonitis: report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol. 1989;84(5):839–44.CrossRef
4.
Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314–24.CrossRef
5.
Quirce S, Vandenplas O, Campo P, Cruz MJ, de Blay F, Koschel D, Moscato G, Pala G, Raulf M, Sastre J, Siracusa A. Occupational hypersensitivity pneumonitis: an EAACI position paper. Allergy. 2016;71(6):765–79.CrossRef
6.
Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196(6):680–9.CrossRef
7.
•• Pérez ER, Travis WD, Lynch DA, Brown KK, Johannson KA, Selman M, Ryu JH, Wells AU, Huang YC, Pereira CA, Scholand MB. Diagnosis and evaluation of hypersensitivity pneumonitis: chest guideline and expert panel report. Chest. 2021 Aug 1;160(2):e97–156. These diagnostic guidelines on hypersensitivity pneumonitis endorsed a multimodality approach and the crux formed by radiology for its diagnosis with limited utility of previously used serological tests.
8.
•• Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36–69. First diagnostic guidelines on hypersensitivity pneumonitis. They emphasized the core role of radiology in its diagnosis and proposed a new radiological and pathological classification for its two phenotypes.
9.
Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J. 2001;18(32 suppl):114s-s118.
10.
Kreuter M, Herth FJ, Wacker M, Hammerl P, Wiederhold C, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D. Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases).
11.
Moore I, Wrobel J, Rhodes J, Lin Q, Webster S, Jo H, Troy L, Grainge C, Glaspole I, Corte TJ. Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulm Med. 2020;20(1):1.CrossRef
12.
Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya P, Gupta R. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med. 2017 Mar 15;195(6):801–13.
13.
Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, Aggarwal AN, Behera D. Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS One. 2018;13(2): e0191938.CrossRef
14.
Fernández Pérez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc. 2018;15(4):460–9.CrossRef
15.
Rittig AH, Hilberg O, Ibsen R, Løkke A. Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study. ERJ Open Res. 2019 Oct 1;5(4).
16.
Dhooria S, Sehgal IS, Agarwal R, Muthu V, Prasad KT, Kathirvel S, Garg M, Bal A, Aggarwal AN, Behera D. Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects. PLoS One. 2022;17(7): e0271665.CrossRef
17.
Dakhama A, HEGELE RG, Laflamme G, Israel-Assayag E, Cormier Y. Common respiratory viruses in lower airways of patients with acute hypersensitivity pneumonitis. Am J Respir Crit Care Med. 1999 Apr 1;159(4):1316–22.
18.
Hoppin JA, Umbach DM, Kullman GJ, Henneberger PK, London SJ, Alavanja MC, Sandler DP. Pesticides and other agricultural factors associated with self-reported farmer’s lung among farm residents in the Agricultural Health Study. Occup Environ Med. 2007;64(5):334–41.CrossRef
19.
Singh S, Collins BF, Bairwa M, Joshi JM, Talwar D, Singh N, Samaria JK, Mangal DK, Singh V, Raghu G. Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India. Eur Respir J. 2019 Feb 1;53(2).
20.
Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. In Mayo Clin Proc. 2007 Jul 1;82(7):812–816. Elsevier.
21.
Glazer C, Martyny J, Rose C. Hot tub associated granulomatous lung disease from mycobacterial bioaerosols. Clin Pulm Med. 2008;15(3):138–44.
22.
Gupta A, Rosenman KD. Hypersensitivity pneumonitis due to metal working fluids: sporadic or under reported? Am J Ind Med. 2006;49(6):423–33.CrossRef
23.
Koschel D, Wittstruck H, Renck T, Müller-Wening D, Höffken G. Presenting features of feather duvet lung. Int Arch Allergy Immunol. 2010;152(3):264–70.CrossRef
24.
Furuiye M, Miyake S, Miyazaki Y, Ohtani Y, Inase N, Umino T, Yoshizawa Y. Effect of cigarette smoking on the development of murine chronic pigeon breeder’s lung The difference between a short-term and a long-term exposure. J Med Dent Sci. 2007;54(1):87–95.
25.
Sharma BB, Singh S, Singh V. Hypersensitivity pneumonitis: the dug-well lung. In Allergy Asthma Proc 2013 Nov 1;34(6):e59–64.
26.
Møller J, Hyldgaard C, Kronborg-White SB, Rasmussen F, Bendstrup E. Hypersensitivity pneumonitis among wind musicians–an overlooked disease? Eur Clin Respir. 2017;4(1):1351268.
27.
Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168(8):952–8.CrossRef
28.
Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SL, Ley B. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis. An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018 Apr 15;197(8):1036–44.
29.
Singh S, Sharma BB, Bairwa M, Gothi D, Desai U, Joshi JM, Talwar D, Singh A, Dhar R, Sharma A, Ahluwalia B. Management of interstitial lung diseases: a consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India: Official Organ of Indian Chest Society. 2020;37(4):359.CrossRef
30.
Suhara K, Miyazaki Y, Okamoto T, Yasui M, Tsuchiya K, Inase N. Utility of immunological tests for bird-related hypersensitivity pneumonitis. Respir Investig. 2015;53(1):13–21.CrossRef
31.
Masuo M, Miyazaki Y, Suhara K, Ishizuka M, Fujie T, Inase N. Factors associated with positive inhalation provocation test results in subjects suspected of having chronic bird-related hypersensitivity pneumonitis. Respir Investig. 2016;54(6):454–61.CrossRef
32.
Muñoz X, Sánchez-Ortiz M, Torres F, Villar A, Morell F, Cruz MJ. Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis. Eur Respir J. 2014;44(6):1658–65.CrossRef
33.
Ohtani Y, Kojima K, Sumi Y, Sawada M, Inase N, Miyake S, Yoshizawa Y. Inhalation provocation tests in chronic bird fancier’s lung. Chest. 2000;118(5):1382–9.CrossRef
34.
Mendoza F, Melendro EI, Baltazares M, Banales JL, Ximenez C, Chapela R, Selman M. Cellular immune response to fractionated avian antigens by peripheral blood mononuclear cells from patients with pigeon breeder’s disease. J Lab Clin Med. 1996;127(1):23–8.CrossRef
35.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44–68.
36.
Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016;71(10):951–4.CrossRef
37.
Baur X, Fischer A, Budnik LT. Spotlight on the diagnosis of extrinsic allergic alveolitis (hypersensitivity pneumonitis). J Occup Med Toxicol. 2015;10(1):1–6.CrossRef
38.
Pérez ER, Swigris JJ, Forssén AV, Tourin O, Solomon JJ, Huie TJ, Olson AL, Brown KK. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144(5):1644–51.CrossRef
39.
De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Verleden GM, Wuyts WA. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8(1):14.CrossRef
40.
Millerick-May ML, Mulks MH, Gerlach J, Flaherty KR, Schmidt SL, Martinez FJ, LeVeque RM, Rosenman KD. Hypersensitivity pneumonitis and antigen identification–an alternate approach. Respir Med. 2016;1(112):97–105.CrossRef
41.
Cormier Y, Letourneau L, Racine G. Significance of precipitins and asymptomatic lymphocytic alveolitis: a 20-yr follow-up. Eur Respir J. 2004;23(4):523–5.CrossRef
42.
Cormier Y, Bélanger J, Durand P. Factors influencing the development of serum precipitins to farmer’s lung antigen in Quebec dairy farmers. Thorax. 1985;40(2):138–42.CrossRef
43.
Morell F, Villar A, Montero MÁ, Muñoz X, Colby TV, Pipvath S, Cruz MJ, Raghu G. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med. 2013;1(9):685–94.CrossRef
44.
De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Verleden GM, Verleden SE, Wuyts WA. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Res J. 2020 Apr 1;55(4).
45.
Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14.CrossRef
46.
Poletti V, Chilosi M, Olivieri D. Diagnostic invasive procedures in diffuse infiltrative lung diseases. Respiration. 2004;71(2):107–19.CrossRef
47.
Mukherjee S, Spiteri M. Transbronchial biopsy and usual interstitial pneumonia: a step forward in disease management. Chest. 2006;130(5):1628–9.CrossRef
48.
Trahan S, Hanak V, Ryu JH, Myers JL. Role of surgical lung biopsy in separating chronic hypersensitivity pneumonia from usual interstitial pneumonia/idiopathic pulmonary fibrosis*: analysis of 31 biopsies from 15 patients. Chest. 2008;134(1):126–32.CrossRef
49.
Ganganah O, Guo SL, Chiniah M, Li YS. Efficacy and safety of cryobiopsy versus forceps biopsy for interstitial lung diseases and lung tumors: a systematic review and meta-analysis. Respirology. 2016;21(5):834–41.CrossRef
50.
Iftikhar IH, Alghothani L, Sardi A, Berkowitz D, Musani AI. Transbronchial lung cryobiopsy and video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse parenchymal lung disease. A meta-analysis of diagnostic test accuracy. Ann Am Thorac Soc. 2017 Jul;14(7):1197–211.
51.
Han Q, Luo Q, Xie JX, Wu LL, Liao LY, Zhang XX, Chen RC. Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2015;149(5):1394–401.CrossRef
52.
Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 2016 May 15;193(10):1161–7.
53.
Raj R, Brown KK. Mortality related to surgical lung biopsy in patients with interstitial lung disease. The devil is in the denominator. Am J Respir Crit Care Med. 2016 May 15;193(10):1082–4.
54.
• Nishida T, Kawate E, Ishiguro T, Kanauchi T, Shimizu Y, Takayanagi N. Antigen avoidance and outcome of nonfibrotic and fibrotic hypersensitivity pneumonitis. ERJ Open Res. 2022 Jan 1;8(1). The study highlights the repercussions of persistent antigenic exposure, leading to recurrence of the disease or its progression to fibrosis.
55.
Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer’s lung 1–3. Am Rev Respir Dis. 1992;145:3–5.CrossRef
56.
Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé BP, Wolters PJ, Collard HR. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619–25.CrossRef
57.
Fiddler CA, Simler N, Thillai M, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis—a single-centre experience. Clin Respir J. 2019;13(12):791–4.CrossRef
58.
Adegunsoye A, Oldham JM, Pérez ER, Hamblin M, Patel N, Tener M, Bhanot D, Robinson L, Bullick S, Chen L, Hsu S. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res. 2017 Jul 1;3(3).
59.
Alexandre AT, Martins N, Raimundo S, Melo N, Mota PC, e Bastos HN, Pereira JM, Cunha R, Guimarães S, Moura CS, Morais A. Impact of azathioprine use in chronic hypersensitivity pneumonitis patients. Pulm Pharmacol Ther. 2020 Feb 1;60:101878.
60.
Raimundo S, Pimenta AC, Cruz-Martins N, Rodrigues MC, Melo N, Mota PC, Sokhatska O, Bastos HN, Beltrão M, Guimarães S, Moura CS. Insights on chronic hypersensitivity pneumonitis’ treatment: factors associated with a favourable response to azathioprine. Life Sci. 2021;1(272): 119274.CrossRef
61.
Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax. 2013;68(8):780–1.CrossRef
62.
Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9.CrossRef
63.
Tamm AM, Kremens K. Rituximab for salvage therapy of refractory hypersensitivity pneumonitis. WMJ. 2019;118(2):95–7.
64.
Ferreira M, Borie R, Crestani B, Rigaud P, Wemeau L, Israel-Biet D, Leroy S, Quétant S, Plantier L, Dalphin JC, Cottin V. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): a retrospective, multicentric, observational study. Respir Med. 2020;1(172): 106146.CrossRef
65.
•• Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh S, Stowasser S, Coeck C, Goeldner RG, Clerisme-Beaty E. Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial. Break-through trial in the management of non-IPF progressive fibrosing ILD. It proved the efficacy of nintedanib in reducing the rate of FVC decline, thus establishing a definitive role in the treatment of patients with progressive fibrosing ILD other than IPF.
66.
• Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine. 2020;8(5):453–60. This subgroup analysis of the INBUILD trial found that the efficacy of nintedanib in reducing the rate of FVC decline was sustained in the sub-population of chronic HP patients.
67.
• Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021;22(1):1–9. The study found no effect of commonly used immunomodulatory drugs on the efficacy of nintedanib in reducing the decline of FVC in patients with progressing fibrosing ILD other than IPF.
68.
• Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet. 2021;9(5):476–86. It was the first randomized double blind placebo controlled trial of pirfenidone in non IPF progressive fibrosing ILD. Though prematurely terminated, the methodology and results open avenues for conducting future studies on the role of pirfenidone.
69.
Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntassiou M, Avdoula E, Trachalaki A, Antoniou K, Raghu G, Bouros D. Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Res. 2020 Oct 1;6(4).
70.
Shibata S, Furusawa H, Inase N. Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):139.
71.
Mateos-Toledo H, Mejía-Ávila M, Rodríguez-Barreto Ó, Mejía-Hurtado JG, Rojas-Serrano J, Estrada A, Castillo-Pedroza J, Castillo-Castillo K, Gaxiola M, Buendía-Roldan I, Selman M. An open-label study with pirfenidone on chronic hypersensitivity pneumonitis. Arch Bronconeumol. 2020;56(3):163–9.CrossRef
72.
Kern RM, Singer JP, Koth L, Mooney J, Golden J, Hays S, Greenland J, Wolters P, Ghio E, Jones KD, Leard L. Lung transplantation for hypersensitivity pneumonitis. Chest. 2015;147(6):1558–65.CrossRef
Metadata
Title
New Paradigms in Hypersensitivity Pneumonitis
Authors
Bineet Ahluwalia
Sheetu Singh
Publication date
08-10-2022
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2022
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-022-00295-5

Other articles of this Issue 4/2022

Current Pulmonology Reports 4/2022 Go to the issue

Interstitial Lung Disease (S Dhooria, Section Editor)

Management of Sarcoidosis: When to Treat, How to Treat and for How Long?

Sleeping and Breathing (A Abreu, Section Editor)

Comorbid Narcolepsy and Obstructive Sleep Apnea: A Review

Environmental and Occupational Health (S Cherian, Section Editor)

The Threat of Wildfires and Pulmonary Complications: A Narrative Review

Environmental and Occupational Health (S Cherian, Section Editor)

Updates in Hypersensitivity Pneumonitis: A Narrative Review

Interstitial Lung Disease (S Dhooria, Section Editor)

Interstitial Pneumonia with Autoimmune Features: Implications for Clinical Practice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits